Clinical Trial Update: An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated beloranib for efficacy, safety, and pharmacokinetics in obese subjects with hypothalamic injury, including craniopharyngioma; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma
• Hypothalamic Obesity
• Obesity

Drugs mentioned

• Beloranib (Beloranib)

Snippet

Sponsor: Zafgen, Inc. | Conditions: Obesity, Over-weight | Phase 2 | Status: COMPLETED